Medical Oncologist
Metastatic breast cancer
Treatment options in metastatic triple negative breast cancer
Metastatic triple negative breast cancer is mainly treated with chemotherapy, with immunotherapy added for PD-L1 positive cancer, PARP inhibitors for BRCA carriers and antibody-drug conjugates in later lines. Testing guides each choice. This page explains the options honestly.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What are the treatment options for metastatic triple negative breast cancer?
- Results that shape your options
- Treatment options by situation, in general terms
- The vocabulary, in plain language
- Honest expectations with metastatic triple negative breast cancer
- What to know about immunotherapy side effects
- Living with treatment for triple negative breast cancer
- Questions to ask about your treatment options
- BRCA testing and what it means for treatment and family
- What people assume about triple negative disease
- Common questions about metastatic triple negative treatment
The short answer
What are the treatment options for metastatic triple negative breast cancer?
Triple negative breast cancer has no oestrogen receptors, no progesterone receptors and does not make excess HER2. Because of this, hormone therapy and standard HER2 treatments do not work, and chemotherapy has long been the main treatment. Over recent years, several newer approaches have been added, and treatment is now increasingly guided by tests on the cancer and on inherited genes. For metastatic triple negative breast cancer, first-line treatment is usually chemotherapy. If the cancer tests positive for a marker called PD-L1, an immunotherapy medicine may be added to chemotherapy, which helps some people keep the cancer under control for longer and live longer. People with an inherited BRCA mutation may be offered a PARP inhibitor tablet, or platinum chemotherapy, which works particularly well in this group. In second and later lines, antibody-drug conjugates, which deliver chemotherapy directly to cancer cells, have shown clear benefit, including one that targets a protein called TROP2 and another for cancers that are HER2-low. Different chemotherapy medicines can also be used one after another. Triple negative cancer can grow more quickly than other types, so timely testing and treatment decisions matter.
Tests before treatment
A biopsy of a metastatic area confirms triple negative status and checks HER2-low and PD-L1. A blood test for inherited BRCA mutations is usually offered.
Why speed matters
Because this type can progress faster, results are ideally available before or soon after starting treatment, so the best combination is chosen early.
Clinical trials
Many new treatments are being tested for triple negative breast cancer, so asking about trials at every stage is worthwhile.
This page gives general information only. Your oncologist will recommend the treatment that suits you.Tests that guide treatment
Results that shape your options
Each test can open a different treatment path.
PD-L1
A marker on cancer and immune cells that shows whether immunotherapy is likely to help.
Different tests use different cut-offs.Inherited BRCA
A blood test for inherited mutations that may make PARP inhibitors and platinum chemotherapy suitable.
HER2-low
Small amounts of HER2 that may allow a HER2-low antibody-drug conjugate.
Receptor recheck
Confirms the cancer is still triple negative, as receptors occasionally change.
Sometimes also tested
- Other tumour gene changes
- Mismatch repair status
- Tumour mutation burden
A general map
Treatment options by situation, in general terms
Situation
Options often discussed
PD-L1 positive, first line
Chemotherapy with immunotherapy
PD-L1 negative, first line
Chemotherapy, chosen by previous treatment and health
Inherited BRCA mutation
PARP inhibitor tablets or platinum chemotherapy
Second line and beyond
TROP2-directed antibody-drug conjugate, or HER2-low conjugate when suitable
Later lines
Other chemotherapy medicines, clinical trials and supportive care
Not sure whether this applies to you?
Ask an oncologistWords you will hear
The vocabulary, in plain language
- Triple negative
- Cancer without oestrogen receptors, progesterone receptors or excess HER2.
- Immunotherapy
- Treatment that helps the immune system recognise and attack cancer.
- PD-L1
- A protein that cancer uses to hide from the immune system.
- PARP inhibitor
- A tablet that targets cancers with BRCA mutations.
- TROP2
- A protein on many triple negative cancer cells, used as a target.
- Antibody-drug conjugate
- An antibody linked to chemotherapy that delivers it into cancer cells.
Being straight with you
Honest expectations with metastatic triple negative breast cancer
Metastatic triple negative breast cancer is often more challenging to control than other types, and many people find information about it frightening. It is important to know both the difficulties and the real progress.
Responses can be shorter
On average, treatments control triple negative cancer for shorter periods than hormone-positive cancer. However, some people respond very well and live well for a long time, particularly with immunotherapy.
Newer treatments have helped
Immunotherapy, PARP inhibitors and antibody-drug conjugates have all improved outcomes in selected groups.
Side effects differ
Immunotherapy can cause immune-related inflammation of the thyroid, bowel, liver, lungs or skin. Antibody-drug conjugates can cause low counts, loose motions and hair loss.
Access and cost
Some newer treatments are expensive. Ask about access programmes and trials.
What this page cannot tell you
It cannot predict your course. Ask your oncologist what treatment aims to achieve.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Immunotherapy
What to know about immunotherapy side effects
Immunotherapy releases a brake on the immune system. Most people tolerate it well, but the immune system can sometimes attack healthy organs, and these effects can appear at any time, even after treatment ends.
Thyroid changes
Tiredness, weight changes, feeling hot or cold, or a racing heartbeat can signal a thyroid problem. Thyroid blood tests are done regularly, and tablets can correct it.
Bowel inflammation
Loose motions, stomach pain or blood in the stool must be reported promptly, as early steroids work well.
Skin, liver and lungs
Rash, itching, yellowing of the eyes, dark urine, a new cough or breathlessness need prompt review.
Hormone glands
Severe tiredness, headaches or dizziness may signal effects on other hormone glands.
Carry an alert card
Tell any doctor you see that you are having immunotherapy, as its side effects can be mistaken for other illnesses.
Daily life
Living with treatment for triple negative breast cancer
Treatment schedules can be intensive, but practical planning helps you keep as much normal life as possible.
Plan around treatment days
Most chemotherapy and antibody-drug conjugates are given every one to three weeks. Energy often dips a few days after each dose, so plan important activities for better days.
Protect against infection
Wash hands often, avoid people who are unwell and check your temperature if you feel shivery. Fever needs same-day care.
Eat and move
Small, frequent meals and gentle daily walking help energy and mood.
Emotional support
Triple negative breast cancer often affects younger women. Support groups and counselling can help with the particular pressures of work, children and relationships.
At your appointment
Questions to ask about your treatment options
Written questions help you understand your choices and make decisions quickly when needed.
About testing
Has my cancer been tested for PD-L1 and HER2-low? Have I been offered inherited BRCA testing?
About treatment
Why is this treatment recommended first? What side effects should I report straight away? When will we check whether it is working?
About the future
What options come next if this stops working? Is there a clinical trial I could join?
Inherited genes
BRCA testing and what it means for treatment and family
Triple negative breast cancer is more often linked to inherited BRCA mutations than other types, especially in younger women and those with a family history of breast or ovarian cancer. Testing is usually offered to everyone with metastatic triple negative breast cancer, whatever their age.
How testing works
A blood or saliva sample is sent for genetic analysis, ideally with counselling before and after, so you understand what the results could mean for you and your relatives.
If a mutation is found
PARP inhibitor tablets and platinum chemotherapy may be offered. Relatives, including brothers, sisters and adult children, may choose testing and, if they carry the mutation, screening or risk-reducing options.
If no mutation is found
Other treatment options remain, and your family history may still be reviewed to guide relatives' screening.
Emotional impact
Genetic results can raise guilt, worry or tension within families. Genetic counsellors and support groups help families talk about this.
Commonly believed
What people assume about triple negative disease
Only chemotherapy works for triple negative cancer.
Immunotherapy, PARP inhibitors and antibody-drug conjugates help selected people.
Testing does not matter because there are no targets.
PD-L1, BRCA and HER2-low results can change treatment.
Immunotherapy has no serious effects.
Immune-related side effects need prompt reporting and treatment.
Everyone with triple negative spread does badly.
Outcomes vary, and some people respond well for years.
Questions we are asked
Common questions about metastatic triple negative treatment
How is PD-L1 tested?
It is tested on a tissue sample, from a new biopsy or stored tissue, in the laboratory.
Can I have immunotherapy if PD-L1 is negative?
In metastatic disease it is usually offered only when PD-L1 is positive. Ask about trials.
Do PARP inhibitors cause hair loss?
Hair loss is uncommon. Tiredness, nausea and low blood counts are more typical.
How long does treatment continue?
As long as it controls the cancer and side effects are manageable.
Should my family have BRCA testing?
If you carry a mutation, relatives may be offered testing with counselling.
Can I work during treatment?
Some people do, with flexible hours around treatment days.
Can I get a second opinion?
Yes. Bring pathology, PD-L1 and genetic results, and scans.
Who helps with cost?
Financial counsellors can explain schemes and access programmes.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- European Society for Medical Oncology — Metastatic breast cancer clinical practice guideline
- American Society of Clinical Oncology — Chemotherapy and targeted therapy for HER2-negative metastatic breast cancer guideline
- National Cancer Institute — Triple-negative breast cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.